Português

Inglês

Home | Site Map | Add to Favorites Link | Send page to a Friend | Contact us

All Content

Publicações científicas e monografias

Journal of Ovarian Research (2018) 11:8

P-MAPA immunotherapy potentiates the effect of cisplatin on serous ovarian carcinoma through targeting TLR4 signaling

International Immunopharmacology

International Immunopharmacology : Effects of P-MAPA immunomodulator on Toll-like receptor 2, ROS, nitric oxide, MAPKp38 and IKK in PBMC and macrophages from dogs with visceral leishmaniasis

International Journal of Clinical and Experimental Pathology-Volume 8, Number 5:4277-6011;2015

Alterations in Ubiquitin Ligase Siah-2 and its Corepressor N-CoR after P-MAPA Immunotherapy and Anti-androgen Therapy: New Therapeutic Opportunities for Non-Muscle Invasive Bladder Cancer

BMC CANCER

Increased toll-like receptors and p53 levels regulate apoptosis and angiogenesis in non-muscle invasive bladder cancer: mechanism of action of P-MAPA biological response modifier

INTERNATIONAL BRAZ J UROL

Potential therapeutic strategies for non - muscle invasive bladder cancer based on association of intravesical immunotherapy with P-MAPA and systemic administration of cisplatin and doxorubicin

Revistas e artigos de divulgação

P-MAPA against visceral leishmaniaisis

Lethal infection caused by a single cell parasite, visceral leishmaniasis spreads throughout Brazilian cities.Among the compounds currently being tested against leishmaniasis, at least one was entirely developed in Brazil by the research network Farmabrasilis. The compound is P-MAPA, an acronym for protein magnesium ammonium phospholinoleate anhydride polymer. In tests conducted in Brazil and in the United States, it has proven to be effective against Listeria monocytoges bacteria, whose survival mechanism in the organism is similar to that of the protozoa of the Leishmania genera.

TropiKA: Brazil-based network proposes new therapeutic approach for TB and other infectious diseases - April 2009

TropIKA: Farmabrasilis is a non-governmental, non-profit research network bringing together Brazilian, Chilean, American and European scientists and others whose concern is: “The research and development of new medicines and technologies for the benefit of economically disadvantaged populations and individuals affected by neglected diseases”.

TropIKA : News from Farmabrasilis - April 2010

Tests carried out by Tuberculosis Antimicrobial Acquisition and Coordinating Facility (TAACF) under contract signed by Farmabrasilis and US NIAID has shown that P-MAPA is active against M. tuberculosis in vivo.

THE LANCET - September 2010

A versatile new drug candidate called P-Mapa along with a new proposal to fight infectious diseases have emerged in Brazil. They are the result of collaboration among non-academic and academic groups in Brazil, Chile and the US led by the non-profit research network Farmabrasilis

Nature Medicine- October 2011

Biomedicine in Brazil : Laws hinder drug development inspired by Amazonian biodiversity

[ First ] [ Previous ] [ 1 ] [ 2 ] [ 3 ] [ 4 ] [ 5 ] [ 6 ] [ 7 ] [ 8 ] [ 9 ] [ 10 ] [ Next ] [ Last ]

Lógica Digital

Privacy Policy | Legal | [email protected] all rights reserved